Journal
PHARMACOGENOMICS
Volume 15, Issue 7, Pages 933-939Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.14.54
Keywords
antipsychotic response; biomarker; CATIE trial; weight gain
Categories
Funding
- National Institutes of Mental Health [MH078437, N01 MH900001, MH074027]
- Eli Lilly and Company
Ask authors/readers for more resources
Aim: Antipsychotic efficacy biomarkers have the potential to improve outcomes in psychotic patients. This study examined the effect of SULT4A1-1 haplotype status (rs2285162 [A]-rs2285167 [G]) on olanzapine response. Patients & methods: We evaluated 87 olanzapine treated subjects from Phases 1, 1B and 2 of the CATIE trial for the impact of SULT4A1-1 status on change in Positive and Negative Syndrome Scale (PANSS) total score using two models of response. We also examined weight change. Results: SULT4A1-1-positive status correlated with superior olanzapine response in Phase 1 (p=0.004 for model 1 and p=0.001 for model 2) and Phases 1B/2 (p=0.05 formodel 1 and p=0.007 for model 2). SULT4A1-1-positive subjects gained significantly less weight per month on olanzapine, 0.15 lbs, than did SULT4A1-1-negative subjects, 2.27 lbs (p=0.04). Conclusion: This study provides a second replication of superior olanzapine response in SULT4A1-1-positive subjects compared with SULT4A1-1-negative subjects. SULT4A1-1-positive subjects treated with olanzapine also gained less weight than SULT4A1-1-negative subjects. Original submitted 19 December 2013; Revision submitted 17 March 2014
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available